BioCentury
ARTICLE | Clinical News

Elotuzumab: Additional Phase II data

December 17, 2012 8:00 AM UTC

Additional data from an open-label Phase II trial in 73 patients with previously treated MM showed that 20 mg/kg elotuzumab plus Revlimid lenalidomide and low-dose dexamethasone led to a median PFS of 18.6 months and an ORR of 76%. In patients receiving 10 mg/kg elotuzumab plus Revlimid and low-dose dexamethasone, median PFS has not been reached after 20.8 months of follow-up and the ORR was 92%. The most common >=grade 3 adverse events were lymphopenia, neutropenia, thrombocytopenia, anemia, leukopenia, hyperglycemia, pneumonia, diarrhea, fatigue and hypokalemia. Patients received 10 or 20 mg/kg IV elotuzumab on days 1, 8, 15 and 22 of a 28-day cycle in the first 2 cycles and then days 1 and 15 of each subsequent cycle plus Revlimid and low-dose dexamethasone. Data were presented at the American Society of Hematology meeting in Atlanta. ...